JPMorgan Chase & Co. Sells 228,182 Shares of Vera Therapeutics, Inc. $VERA

JPMorgan Chase & Co. cut its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 73.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,365 shares of the company’s stock after selling 228,182 shares during the period. JPMorgan Chase & Co. owned approximately 0.13% of Vera Therapeutics worth $2,394,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in Vera Therapeutics during the second quarter valued at approximately $51,000. Tower Research Capital LLC TRC lifted its stake in shares of Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares during the last quarter. AlphaQuest LLC lifted its stake in shares of Vera Therapeutics by 414.2% in the 3rd quarter. AlphaQuest LLC now owns 5,214 shares of the company’s stock valued at $152,000 after purchasing an additional 4,200 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Vera Therapeutics in the 3rd quarter valued at approximately $264,000. Finally, Perigon Wealth Management LLC lifted its stake in shares of Vera Therapeutics by 23.9% in the 3rd quarter. Perigon Wealth Management LLC now owns 12,898 shares of the company’s stock valued at $375,000 after purchasing an additional 2,492 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Price Performance

VERA opened at $40.44 on Tuesday. The business has a fifty day moving average of $41.50 and a 200 day moving average of $38.79. The stock has a market cap of $2.89 billion, a P/E ratio of -8.68 and a beta of 1.17. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $56.05. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same quarter last year, the company earned ($0.72) earnings per share. As a group, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. HC Wainwright raised their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Evercore raised their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. Bank of America raised their price objective on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, The Goldman Sachs Group raised their price objective on Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $81.45.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, insider William D. Turner sold 2,187 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $91,810.26. Following the completion of the sale, the insider directly owned 45,313 shares of the company’s stock, valued at $1,902,239.74. The trade was a 4.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO David Lee Johnson sold 2,579 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $108,266.42. Following the sale, the chief operating officer directly owned 45,727 shares of the company’s stock, valued at approximately $1,919,619.46. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,490 shares of company stock worth $1,405,910 over the last quarter. Insiders own 16.30% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.